We have one of the largest specialist biotech teams in Europe supporting global biotech companies at all stages of development, innovation, and growth. Our clients are diverse and include therapeutics companies, suppliers of research tools, companion diagnostics, and other in vitro diagnostics and bio information solutions. Our expertise extends to broader applications of biotech across environmental, industrial, and agri-biotech.
With legal expertise grounded in scientific know-how, our support incorporates company formation, spin-out accelerator programmes, venture capital fundraisings, licensing and collaborations, clinical trials, and strategic alliances in addition to accessing capital markets and deploying intellectual property rights.
Clients value our long-held industry connections and our specialist sector expertise. Our global team is embedded in this industry with experience across many technologies, including vaccines, therapeutic proteins, monoclonal antibodies, immune-oncology, and cell-based therapies, gene therapies, and tissue-engineered products.
We are chosen by renowned biotech companies for our expertise in negotiating on pivotal IP licensing deals, resolving disputes with strategic partners, dealing with data privacy issues and avoiding competition/anti-trust risks. With our support, they push innovation boundaries and exploit commercial opportunities while remaining secure within relevant regulatory regimes.
Actualités et publications récentes
Dual Use Technologies in Biotech and their Regulation in the EU and Germany
Preliminary injunctions in the UPC – lessons learnt
Two years in, the UPC has become a key forum for patent enforcement, offering swift preliminary injunctions across many EU states. Courts assess both infringement and patent validity rigorously, requiring applicants to act quickly and prepare thoroughly.
2 de 5 Publications
UPC litigation in life sciences: seven early takeaways for the pharma, biotech and medical devices sectors
The Unified Patent Court (UPC) has become a crucial forum for life sciences patent litigation. Early rulings show strict claim interpretation, careful review of European Patent Office oppositions, and limits on the Bolar exemption. The UPC has clarified infringement tests for second medical use claims and considers patient interests in injunctions. These developments emphasise precise patent strategy, regulatory alignment, and proactive risk management for pharma, biotech, and medical device sectors.
1 de 5 Publications
Revocation of life sciences patents in the UPC
The Unified Patent Court (UPC), active since June 2023, is seeing strong uptake in pharma and biotech. Revocation decisions show a balanced 50:50 win rate for patentees and challengers. Key legal standards on novelty, obviousness, and inventive step are emerging, though some aspects remain unclear. Strategic use of the UPC offers broad enforcement, but revocation risks are higher for single-patent portfolios. Legal uncertainties, like the Bolar exemption, still need clarification.
4 de 5 Publications
The UPC going beyond its borders: how your company can profit from the latest case law
The UPC now allows life sciences companies to enforce European patents more efficiently across multiple countries through its long-arm jurisdiction. This lets patent holders sue distributors based in UPC member states in a single action, even if products are sold or made in non-UPC countries. Following key rulings the UPC can issue cross-border injunctions covering several national patent parts, while respecting jurisdiction limits on patent validity challenges.
5 de 5 Publications
